Product Details
Inspiolto Respimat
Tiotropium Bromide Monohydrate + Olodaterol Hydrochloride2.5 mcg + 2.5 mcg/Actuation
Solution for Inhalation
60-Actuation Pack
DIN/PIN/NPN
02441888
Manufacturer
Boehringer-Ingelheim (Canada) Ltd./Ltee
Formulary Listing Date
2016-03-30
Unit Price
64.3740
Amount MOH Pays
64.3740
Coverage Status
Limited Use Product
ODB Formulary Therapeutic Classification
Therapeutic Note
Inspiotto Respimat: Each actuation of Inspiotto Respimat contains 2.5mcg of tiotropium, supplied as tiotropium bromide monohydrate, and 2.5mcg of olodaterol, supplied as olodaterol hydrochloride.
ATC Code
R03AL06
Interchangeable Products
NOLU Clinical Criteria
| LU Code | Auth. Period | Clinical Criteria |
|---|---|---|
| 459 | Indefinite | For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD-see notes below) who have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA)). Note: COPD disease severity is based on spirometry, symptoms and disability (see classification tables below). Classification COPD Stages - Symptoms and disability: Mild: Shortness of breath from COPD when hurrying on the level or walking up a slight hill. Moderate: Shortness of breath from COPD causing the patient to stop after walking approximately 100m (or after a few minutes) on the level Severe: Shortness of breath from COPD resulting in the patient being too breathless to leave the house, breathless when dressing or undressing (MRC 5), or the presence of chronic respiratory failure or clinical signs of right heart failure Classification by impairment of lung function: COPD stage and spirometry (post bronchodilator) FEV1 predicted: Mild: Greater than or equal to 80 percent Moderate: 50 to 79 percent Severe: 30 to 49 percent Very severe: Less than 30 percent |